RT Journal Article
SR Electronic
T1 Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.14.21258567
DO 10.1101/2021.06.14.21258567
A1 O’Brien, Meagan P.
A1 Forleo-Neto, Eduardo
A1 Musser, Bret J.
A1 Isa, Flonza
A1 Chan, Kuo-Chen
A1 Sarkar, Neena
A1 Bar, Katharine J.
A1 Barnabas, Ruanne V.
A1 Barouch, Dan H.
A1 Cohen, Myron S.
A1 Hurt, Christopher B.
A1 Burwen, Dale R.
A1 Marovich, Mary A.
A1 Hou, Peijie
A1 Heirman, Ingeborg
A1 Davis, John D.
A1 Turner, Kenneth C.
A1 Ramesh, Divya
A1 Mahmood, Adnan
A1 Hooper, Andrea T.
A1 Hamilton, Jennifer D.
A1 Kim, Yunji
A1 Purcell, Lisa A.
A1 Baum, Alina
A1 Kyratsous, Christos A.
A1 Krainson, James
A1 Perez-Perez, Richard
A1 Mohseni, Rizwana
A1 Kowal, Bari
A1 DiCioccio, A. Thomas
A1 Stahl, Neil
A1 Lipsich, Leah
A1 Braunstein, Ned
A1 Herman, Gary
A1 Yancopoulos, George D.
A1 Weinreich, David M.
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/06/17/2021.06.14.21258567.abstract
AB Background Casirivimab and imdevimab (REGEN-COV™) markedly reduces risk of hospitalization or death in high-risk individuals with Covid-19. Here we explore the possibility that subcutaneous REGEN-COV prevents SARS-CoV-2 infection and subsequent Covid-19 in individuals at high risk of contracting SARS-CoV-2 by close exposure in a household with a documented SARS-CoV-2–infected individual.Methods Individuals ≥12 years were enrolled within 96 hours of a household contact being diagnosed with SARS-CoV-2 and randomized 1:1 to receive 1200 mg REGEN-COV or placebo via subcutaneous injection. The primary efficacy endpoint was the proportion of participants without evidence of infection (SARS-CoV-2 RT-qPCR– negative) or prior immunity (seronegative) who subsequently developed symptomatic SARS-CoV-2 infection during a 28-day efficacy assessment period.Results Subcutaneous REGEN-COV significantly prevented symptomatic SARS-CoV-2 infection compared with placebo (81.4% risk reduction; 11/753 [1.5%] vs. 59/752 [7.8%], respectively; P<0.0001), with 92.6% risk reduction after the first week (2/753 [0.3%] vs. 27/752 [3.6%], respectively). REGEN-COV also prevented overall infections, either symptomatic or asymptomatic (66.4% risk reduction). Among infected participants, the median time to resolution of symptoms was 2 weeks shorter with REGEN-COV vs. placebo (1.2 vs. 3.2 weeks, respectively), and the duration of time with high viral load (>104 copies/mL) was lower (0.4 vs. 1.3 weeks, respectively). REGEN-COV was generally well tolerated.Conclusions Administration of subcutaneous REGEN-COV prevented symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection in uninfected household contacts of infected individuals. Among individuals who became infected, REGEN-COV reduced the duration of symptomatic disease, decreased maximal viral load, and reduced the duration of detectable virus.(ClinicalTrials.gov number, NCT04452318.)Competing Interest StatementICMJE disclosure forms provided by the authors are available with the full text of this article.Clinical TrialNCT04452318Funding StatementSupported by Regeneron Pharmaceuticals, Inc. and F. Hoffmann-La Roche Ltd. This trial was conducted jointly with the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). The CoVPN is supported by cooperative agreement awards from NIAID, NIH. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The work on this study was supported by CoVPN award number UM1AI068619.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the following ethics review boards: WCG IRB, Puyallup, WA (IRB00000533); Lifespan - Rhode Island Hospital IRB 2, Providence, RI (IRB# 00004624); Stanford University Research Compliance Office, Palo Alto, CA (IRB# 00004593); Geisinger Institutional Review Board - GRIB, Danville, PA (IRB00008345); Advarra IRB, Columbia, MD (IRB00000971).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesQualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to https://vivli.org/.